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posterior, or panuveitis are estimated to have a 10-fold increased risk of blindness or low vision, 3, 7 and cumulative damage caused by recurring uveitis flares can increase this risk. 8 Although corticosteroids are the mainstay of uveitis treatment, they are associated with common and potentially serious side effects accompanying long-term and high-dose use. 9e11 Additional therapies would ideally target specific mediators of the immune response underlying uveitic inflammation to achieve disease quiescence and allow reduced corticosteroid burden and related complications, while providing greater efficacy than conventional steroid-sparing immunosuppressive agents. 12 Tumor necrosis factorea (TNF-a) is a cytokine that contributes to inflammation in immune-mediated diseases, including noninfectious uveitis. 9, 13, 14 The human monoclonal antibody to TNF-a, HUMIRA (adalimumab; AbbVie Inc, North Chicago, IL), blocks the interaction between TNFa and its cell surface receptors to inhibit inflammatory TNF-a signaling. 15 Adalimumab is approved for the treatment of several immune-mediated inflammatory diseases, including noninfectious intermediate, posterior, and panuveitis. 12, 16 The efficacy of adalimumab in managing uveitis was demonstrated in 2 randomized, double-masked, placebocontrolled trials of patients with active uveitis despite treatment with high-dose (10e60 mg/day prednisone equivalent) systemic corticosteroids (VISUAL I) 17 or uveitis dependent on higher than recommended 10, 18 doses of systemic corticosteroids for disease control (10e35 mg/day prednisone equivalent; VISUAL II). 19 In the parent studies, treatment failure (TF) was assessed and defined by a rigorous composite end point based on 4 components (new inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, and best-corrected visual acuity [BCVA] ). 17, 19 In these studies, adalimumab effectively reduced the risk of TF compared with placebo in patients with active or inactive uveitis. 17, 19 Furthermore, significantly higher rates of quiescence (defined as no active inflammatory lesions, anterior chamber cell grade 0.5þ, and vitreous haze grade 0.5þ) and corticosteroid-free quiescence were achieved and maintained through 52 weeks in the VISUAL I/II studies in patients receiving adalimumab compared with placebo, regardless of disease status at study entry. 20 The objective of the open-label extension study, VISUAL III, was to evaluate the safety and efficacy of extended adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis who successfully completed the VISUAL I or VISUAL II trials without TF (defined as patients with inactive uveitis in VISUAL III) or experienced TF in the parent trials (defined as patients with active uveitis in VISUAL III). This report describes the interim analysis of VISUAL III through 78 weeks of follow-up.
Methods

Study Design
This was an open-label, multicenter, unmasked, uncontrolled, phase 3 extension study (VISUAL III; registered at www.clinicaltrials.gov, trial ID NCT01148225 and www.clinicaltrialsregister.eu, EudraCT number 2009-016196-29) conducted at sites in Argentina, Australia, Austria, Belgium, Brazil, Canada, the Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Poland, Portugal, Spain, Switzerland, the United Kingdom, and the United States. Study visits occurred at week 0 (baseline); at weeks 2, 4, 8, 12, and 18; and every 12 weeks thereafter. The window for all scheduled visits was AE7 days. The trial extension is ongoing; this report describes follow-up efficacy and safety data through week 78, as of the interim cutoff of October 31, 2016. All patients had the opportunity to reach week 78 before the cutoff date. This interim analysis was conducted to provide real-world data after approval of adalimumab to treat uveitis. Efficacy data were collected from the first adalimumab dose in VISUAL III through 78 weeks of follow-up. Safety data were collected from the first adalimumab dose in VISUAL III and until up to 70 days after the last dose of adalimumab or up to the interim cutoff date of October 31, 2016, whichever occurred first.
The study complied with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice; sites in the United States conformed to the requirements of the Health Insurance Portability and Accountability Act. All patients signed a statement of informed consent before enrollment, and all procedures were reviewed and approved by appropriate institutional review boards or ethics committees before study initiation.
Patients
Eligible patients were aged !18 years and diagnosed with noninfectious intermediate, posterior, or panuveitis. Patients had either discontinued from a phase 3 parent study (VISUAL I, trial ID NCT01138657; or VISUAL II, trial ID NCT01124838) for having met predefined TF criteria or successfully completed the parent study without TF. Randomization from the parent studies was not disclosed before entry in VISUAL III. Enrolled patients were required to complete the VISUAL III baseline visit within 28 days of the final visit of the parent study. Patients who discontinued from a parent study for any reason other than TF were not eligible for participation in VISUAL III.
Key ocular exclusion criteria were corneal or lens opacity that precluded visualization of the fundus or that would likely require cataract surgery during trial participation; intraocular pressure !25 mmHg requiring !2 glaucoma medications, or having evidence of glaucomatous optic nerve injury; BCVA worse than 20/200 (Snellen; equivalent to logMAR >1.0 using an Early Treatment Diabetic Retinopathy Study [ETDRS] chart) in either eye; proliferative or severe nonproliferative diabetic retinopathy; neovascular age-related macular degeneration; or abnormality of the vitreoretinal interface with the potential for macular structural damage independent of the inflammatory process. Nonocular exclusions included a history of or neurologic symptoms suggestive of central nervous system demyelinating disease; evidence of dysplasia or history of malignancy (including lymphoma and leukemia); and treatment with intravenous or oral antibiotics ( 30 or 14 days before the baseline visit, respectively). Complete inclusion and exclusion criteria are listed in Table S1 (available at www.aaojournal.org).
Of 424 patients enrolled and included in the safety data set, 371 were included in the intent-to-treat (ITT) data set ( Fig 1) . Patients (n ¼ 53) were excluded from the ITT set if they developed proliferative or severe nonproliferative diabetic retinopathy or clinically significant macular edema caused by diabetic retinopathy, underwent cataract surgery during the study, or had previous vitrectomy or underwent vitrectomy during the study (i.e., surgeries that could be a reason for a patient's improvement in vision other than the study drug). Additional reasons for exclusion from the ITT set were incomplete efficacy source data in the parent study and general compliance issues at the study site in the parent studies. An additional 5 patients with macular hole or rhegmatogenous retinal detachment were excluded from analysis of central subfield thickness (CST).
Treatment
All patients received open-label subcutaneous adalimumab 40 mg every other week for the duration of the study regardless of treatment assignment in the parent studies. Patients were allowed, at the investigator's clinical discretion throughout the study, to initiate, continue, escalate, or taper concomitant oral or topical corticosteroid therapy (all corticosteroids were systemic unless noted otherwise) and/or any one of the immunosuppressive therapies permitted in the parent study to control intraocular inflammation (methotrexate 25 mg/week; cyclosporine 4 mg/kg/day; mycophenolate mofetil 2 g/day; azathioprine 175 mg/day). Additionally, patients were allowed 2 periocular corticosteroid injections per eye per year; intraocular or intravitreal injections were not allowed.
Outcome Measures
The main outcome measure was quiescence, defined as no active inflammatory chorioretinal and/or inflammatory retinal vascular lesions (inflammatory lesions), anterior chamber cell grade 0.5þ, and vitreous haze grade 0.5þ in both eyes, similar to the quiescence criteria used in the VISUAL I and II trials. 17, 19 Efficacy variables included no active inflammatory lesions, anterior chamber cell grade 0.5þ, vitreous haze grade 0.5þ, central retinal thickness, BCVA, and the dose of uveitis-related corticosteroids and immunomodulators. There was no designated study eye; outcomes were evaluated in both eyes at every study visit from weeks 0 through 78.
The absence or presence of new inflammatory chorioretinal and/or inflammatory retinal vascular lesions (compared with the findings of the final visit of the parent study) was determined using dilated indirect ophthalmoscopy and was based on the investigators' clinical judgment. Vitreous haze was evaluated using dilated indirect ophthalmoscopy and comparison with standard photographs, as described in the National Eye Institute Criteria adapted by the Standardization of Uveitis Nomenclature Working Group (score range, 0 [no vitreous haze] to 4þ [optic nerve head is obscured]). 21, 22 Anterior chamber cells (within a 1 Â 1-mm slit beam) were counted using slit-lamp examination and graded according to Standardization of Uveitis Nomenclature Working Group criteria (score range, 0 [<1 cell in field] to 4þ [>50 cells in field]). 21 Anterior chamber cell evaluation was performed before mydriatic eye drops were instilled to dilate the pupil. CST (center 1-mm subfield) was determined by optical coherence tomography (OCT) with 1 of 3 instruments: Stratus OCT (Carl Zeiss Meditec, Inc, Jena, Germany), Cirrus HD-OCT (Carl Zeiss Meditec, Inc), or Spectralis (Heidelberg Engineering, Heidelberg, Germany). Each system's software identifies the internal limiting membrane as the inner retina. For the outer retinal boundary, the Stratus OCT uses the ellipsoid zone, the Spectralis uses the Bruch membrane, and Cirrus HD-OCT uses the inner third of the retinal pigment epithelium. 23, 24 BCVA was determined for each eye separately using appropriate corrective lenses based on patients' current refraction using a standard ETDRS chart at a distance of 4 or 1 m. BCVA was recorded as the number of letters read and was transformed into logMAR units for analysis. Dose of uveitisrelated corticosteroids was recorded throughout the study, as were the doses of other permitted immunosuppressives.
Safety was monitored through adverse event (AE) collection, physical examination, vital signs, and laboratory testing. AEs were coded using the Medical Dictionary for Regulatory Activities (version 19.0). Active or latent tuberculosis was determined by the investigator.
Statistical Analysis
Efficacy variables were analyzed using data from the ITT data set. Outcomes were analyzed by uveitis status at baseline (active or inactive uveitis as defined above) and overall. Binary data were analyzed descriptively as observed and using the nonresponder imputation (NRI) method, and exact 95% Clopper-Pearson confidence intervals (CIs) were calculated. Corticosteroid dose and corticosteroid-free quiescence were summarized descriptively as observed. BCVA and CST were analyzed descriptively as observed and using last observation carried forward (LOCF) as the imputation method; data from left and right eyes were analyzed separately. CST was analyzed separately for left and right eyes by OCT machine software. The 95% CI for means and logMAR were calculated.
Analysis of AEs was conducted using the safety data set, including all patients who received at least 1 dose of adalimumab. AEs were reported as the total number of events and number of events per 100 patient-years (PY).
Results
Patients
In the ITT set, 49% of patients (182/371) entered from the VISUAL I trial and 51% of patients (189/371) entered from the VISUAL II trial. Most patients were female (58%, 214/371) and white (75%; 277/371) ( Table 1 ). The mean AE standard deviation (SD) patient age was 42.5AE14.0 years, and the mean duration of diagnosed uveitis was 62.7AE67.3 months. At study entry, 65% of patients (242/371) had active uveitis (i.e., experienced TF in VISUAL I or II) and the remaining 35% (129/371) had inactive uveitis (i.e., completed the parent trials without experiencing TF). A total of 121 of 371 (33%) patients were receiving immunomodulators and 151 of 371 (41%) were receiving corticosteroids (systemic and nonsystemic) at VISUAL III baseline; 30 patients (8%) started immunomodulators and 65 patients (18%) started corticosteroids during the study. Throughout VISUAL III, 33 of 371 (9%) patients received concomitant local corticosteroid injections.
As of the interim cutoff, 316 patients (75%) were ongoing, and 108 of the 424 patients (25%) in the safety set discontinued the study before week 78 (Fig 1) . Reasons for premature discontinuation before week 78 were AEs (11%, 48/424), lack of efficacy (5%, 22/424), withdrawal of consent (2%, 9/424), loss to follow-up (1%; 5/424), or other reasons (8%, 32/424).
Quiescence
At week 0 of VISUAL III, 93% of patients defined as having active uveitis (i.e., patients who experienced TF in the parent trials) were not in quiescence (224/242, NRI). By week 12, 60% (144/242, NRI) of patients achieved quiescence, which remained stable at week 78 (60%; 145/242, NRI; Fig 2A) . Of patients who achieved quiescence, 66% were corticosteroid free (95/143, as observed) at week 78, and 23% were receiving corticosteroid doses of 7.5 mg/day (33/143, as observed; Fig 2B) .
Of the patients who entered VISUAL III defined as having inactive uveitis (i.e., patients who completed the parent trials without experiencing TF), 85% met criteria for quiescence at week 0 (109/129, NRI; Fig 2A) . By week 78, the percentage of patients in quiescence remained stable at 74% (96/129, NRI). Of patients in quiescence, 96% (105/109, as observed) were not receiving uveitis-related corticosteroids at week 0, and 93% (89/96, as observed) were not receiving any corticosteroids at week 78 (Fig 2B). Only 2 patients with inactive uveitis at study entry were receiving >7.5 mg/day corticosteroids at week 78 to maintain quiescence. The trends observed in patients who entered VISUAL III with active or inactive uveitis were also reflected in the overall patient population ( Fig S1A and B , available at www.aaojournal.org).
Quiescence data were also analyzed in patients who were stratified by placebo or adalimumab treatment during the parent VISUAL I and VISUAL II trials. At week 0, 27% of patients who received placebo (49/185; NRI) and 42% of patients who received adalimumab (78/186; NRI) during the VISUAL I and II trials were in quiescence. At week 78, 67% of patients who received placebo (124/185; NRI) and 63% of patients who received adalimumab (117/186; NRI) during the VISUAL I and II trials achieved quiescence (Fig S2A, available at www.aaojournal.org). Of patients in quiescence, 80% (99/123; as observed) who received placebo and 73% (85/116; as observed) who received adalimumab during VISUAL I and II trials were corticosteroid free at week 78 ( Fig S2B, available at www.aaojournal.org).
Other Efficacy Variables
Chorioretinal Lesions. In patients with active uveitis at study entry, there was an improvement in percentage of patients with no active chorioretinal lesions, from 64% at week 0 (154/242, NRI) to 83% at week 12 (200/242, NRI), followed by a decline to 69% at week 78 (166/242, NRI) ( Fig 3A) .
Anterior Chamber Activity. The percentage of patients with anterior chamber cell grade 0.5þ in both eyes increased from 50% at week 0 (120/242, NRI) to 81% at week 12 (197/242, NRI), followed by a decline to 66% at week 78 (159/242, NRI) ( Fig 3B) .
Vitreous Activity. The percentage of patients with vitreous haze grade 0.5þ increased from 41% at week 0 (98/242, NRI) to 65% at week 78 (157/242, NRI) ( Fig 3C) .
In patients with inactive uveitis at study entry in VISUAL III, the percentage of patients with no active inflammatory lesions, anterior chamber cell grade 0.5þ, and vitreous haze grade 0.5þ remained stable from week 0 to week 78 (Fig 3) . Efficacy variables in the overall population are described in Figure S3 (available at www.aaojournal.org).
After a small initial decrease, CST was generally stable throughout follow-up, regardless of the OCT machine type used (LOCF; Fig 4AeC) . Patients who entered the study with active uveitis had greater central retinal thickness than those with inactive uveitis observed with the Stratus OCT and Spectralis. CST decreased through week 78 in patients with active uveitis and was generally stable in patients with inactive uveitis. In all left eyes at week 0, mean CST observed with the Stratus OCT, Spectralis, and Cirrus HD-OCT was 246.8 mm (n ¼ 105), 321.2 mm (n ¼ 183), and 302.4 mm (n ¼ 70), respectively, compared with 227.2 mm (n ¼ 72), 295.7 mm (n ¼ 136), and 256.8 mm (n ¼ 56) at week 78 (as observed). In all right eyes at week 0, mean CST observed with the Stratus OCT, Spectralis, and Cirrus HD-OCT was 269.1 mm (n ¼ 105), 311.9 mm (n ¼ 181), and 312.4 mm (n ¼ 71), respectively, compared with 242.6 mm (n ¼ 71), 280.5 mm (n ¼ 135), and 287.9 mm (n ¼ 56) at week 78 (as observed).
For patients with active uveitis, mean change in CST at week 78 from week 8 for the Stratus OCT, Spectralis, and Cirrus HD-OCT was À14.2 mm (95% CI, À30.5 to 2.1), À7.1 mm (95% CI, À17.7 to 3.5), and À27.0 mm (95% CI, À48.0 to À6.0), respectively, for the left eyes and À6.4 mm (95% CI, À30.6 to 17.7), À18.3 mm (95% CI, À30.7 to À5.8), and 1.5 mm (95% CI, À24.0 to 26.9), respectively, for the right eyes (as observed). For patients with inactive uveitis, mean change in CST at week 78 from baseline for the Stratus OCT, Spectralis, and Cirrus HD-OCT was À17.5 mm (95% CI, À30.8 to À4.1), 0 mm (95% CI, À12.4 to 12.4), and À6.3 mm (95% CI, À16.8 to 4.1), respectively, for the left eyes and À35.9 mm (95% CI, À75.5 to À3.8), À11.5 mm (95% CI, À21.5 to À1.5), and À3.1 mm (95% CI, À10.4 to 4.2), respectively, for the right eyes (as observed).
The percentage of eyes with BCVA < 0.05 logMAR increased from week 0 (35%) to week 78 (49%) in patients with active uveitis at study entry but remained stable in eyes with inactive uveitis (63% and 64% at weeks 0 and 78, respectively; as observed; Fig  5A) Fig 5B) . Overall, mean BCVA improved in the left eyes from 0.20 logMAR at week 0 (n ¼ 371; 95% CI, 0.16e0.23) to 0.10 logMAR at week 78 (n ¼ 279; 95% CI, 0.07e0.13) and in the right eyes from 0.19 logMAR at week 0 (n ¼ 371; 95% CI, 0.16e0.22) to 0.11 logMAR at week 78 (n ¼ 279; 95% CI, 0.07e0.15; Fig 5B) .
Among patients with active uveitis at study entry, the observed mean AE SD corticosteroid dose was 13.6AE19.1 mg/day at week 0 (n ¼ 237), 6.1AE9.3 mg/day at week 12 (n ¼ 224), and 2.6AE5.2 mg/day at week 78 (n ¼ 173; Fig 6) , representing an overall mean dose reduction of À11.3 mg/day. The observed mean corticosteroid dose for patients who entered the study with inactive uveitis was low at baseline, with little change throughout the follow-up period (week 0, 1.5AE7.2 mg/day [n ¼ 128]; week 12, 0.9AE4.1 mg/day [n ¼ 119]; week 78, 1.2AE5.0 mg/day [n ¼ 104]; Fig 6) . In the overall population, the observed mean AE SD daily corticosteroid dose was 9.3AE16.9 mg at study entry (n ¼ 365). The observed mean AE SD daily corticosteroid dose decreased by 75% to 2.1AE5.1 mg at week 78 (n ¼ 277; Fig 6) . The change from baseline was À7.1 (95% CI, À9.2 to À5.1).
Of patients who received immunomodulators at baseline, 78% with active uveitis at study entry (36/46; 95% CI, 63.6e89.1; as observed) and 89% with inactive uveitis at study entry (32/36; 95% CI, 73.9e96.9; as observed) still received immunomodulators at week 78. However, at week 78 there was a 26% mean decrease in the dose of immunomodulators compared with week 8 of VISUAL III for patients with active uveitis at study entry (n ¼ 47; 95% CI, À39.6 to À11.5) and a 15% mean decrease in dose compared with week 0 of VISUAL III for patients with inactive uveitis at study entry (n ¼ 37; 95% CI, À26.1 to À4.7). Additionally, at week 78, 47% of patients with active uveitis at study entry achieved a !50% reduction in immunosuppression load (corticosteroids and/or immunomodulators) compared with week 8 (52/110; 95% CI, 37.7e57.0; as observed), whereas 13% of patients with inactive uveitis at study entry achieved a !50% reduction in immunosuppression load (corticosteroids and/or immunomodulators) compared with week 0 (5/39; 95% CI, 4.3e27.4; as observed).
Safety
For all patients enrolled in VISUAL III (N ¼ 424), mean AE SD exposure to adalimumab was 117AE70 weeks, representing 953.7 PY of exposure. The overall exposure-adjusted rate of any AE was 424 events/100 PY. As summarized in Table 2 , there were 82 AEs leading to study discontinuation (8.6 events/100 PY; Table S2 , available at www.aaojournal.org), 157 serious AEs (16.5 events/ 100 PY), of which 36 (3.8 events/100 PY; Table S3 , available at www.aaojournal.org) were judged by the investigators as at least possibly related to adalimumab, and 30 nonserious allergic reactions (3.2/100 PY). There was a low incidence of active tuberculosis (0.1 event/100 PY), opportunistic infections (0.5 events/100 PY), serious infections (4.0 events/100 PY), and malignancies (1.3 events/100 PY). Fifteen patients (1.6 events/ 100 PY) described asymptomatic latent tuberculosis based on the positive findings of annual tuberculosis testing. The event of active tuberculosis was considered not related to adalimumab by the investigator and probably related to adalimumab by the sponsor. Study drug was discontinued in this patient with active tuberculosis, and antituberculosis therapy was provided. Five patients (0.5 events/100 PY) experienced demyelinating disorders, including multiple sclerosis (n ¼ 1), demyelination (n ¼ 2; 1 case with magnetic resonance imaging [MRI] was suggestive of multiple sclerosis), and optic neuritis (n ¼ 2; neither MRI showed central nervous system findings of demyelination). All 5 patients with demyelinating disorders were discontinued from the study. Two of these patients had intermediate uveitis, 2 had posterior uveitis, and 1 had panuveitis. The 1 patient with multiple sclerosis had intermediate uveitis and was reported to have an abnormal baseline MRI. Four deaths (0.4 events/100 PY) were reported (1 event each of metastatic pancreatic carcinoma, brain abscess, B-cell lymphoma [without ocular involvement], and accidental death). All fatal events except brain abscess (possibly related) were considered by the investigator as not related or probably not related to study drug.
Discussion
Effective corticosteroid-sparing therapies are needed to maintain disease control in eyes with noninfectious intermediate, posterior, and panuveitis and, thereby, to reduce the risk of visual complications and corticosteroid-related side effects.
A substantial proportion of patients who entered VISUAL III with active uveitis (i.e., experienced TF in the parent studies) were in quiescence at week 78 compared with baseline (60% vs. 7%, respectively; NRI). By week 78, two thirds of these patients were in corticosteroid-free quiescence, and only 7% of patients in quiescence were receiving >7.5 mg/day corticosteroids. The majority of patients with inactive uveitis (i.e., did not experience TF in the parent studies) were quiescent at baseline (85%) and the rate of quiescence remained stable (78%) at week 78, on no or low-dose systemic corticosteroids. It is important to emphasize that not all patients responded to adalimumab (40% of patients with active uveitis and 26% of patients with inactive uveitis were not in quiescence at week 78), although these results suggest that adalimumab therapy allows a substantial percentage of patients to achieve corticosteroid-sparing quiescence. These trends were also observed in the overall patient population.
Additionally, at least two thirds of patients with active or inactive uveitis who received adalimumab did not have active inflammatory lesions, had anterior chamber cell and vitreous haze grades 0.5þ in both eyes, and had stable visual acuity during weeks 12 to 78 of follow-up. These results are consistent with both the VISUAL I and II trials, in which eyes treated with adalimumab had a significantly reduced risk of recurrence or worsening of BCVA in patients with uveitis. 17, 19 Until recently, immunosuppressive medications were used routinely as steroid-sparing agents 10 and were termed "conventional" despite being used off label for uveitis. The results of this study confirm and extend the findings of early open-label trials in which treatment with adalimumab enabled substantial tapering of immunosuppressive drugs while achieving disease control in eyes with corticosteroid-resistant uveitis. 25, 26 In groups with and without previous exposure to adalimumab during the VISUAL I and II trials, the percentage of patients in quiescence at baseline was numerically greater in patients who had received adalimumab vs. placebo (42% vs. 27%, respectively). The percentage of patients in quiescence increased from baseline to week 78 in both groups (adalimumab, 42% to 63%; placebo, 27% to 67%; NRI). Of those in quiescence at week 78, a slightly higher percentage of patients who had received placebo vs. those who had received adalimumab in the parent trials were steroid free (80% vs. 73%, respectively).
In the current open-label study, adalimumab controlled multiple signs of uveitic inflammation (i.e., inflammatory lesions, vitreous haze, anterior chamber cells, and central retinal thickening) for up to 78 weeks of follow-up in eyes with active or inactive uveitis at study entry while also permitting a substantial decrease in systemic corticosteroid use in patients who enrolled with active uveitis. At week 78, the as-observed analysis demonstrated that the majority of patients had anterior chamber cell grade 0.5þ or vitreous haze grade 0.5þ and no inflammatory lesions relative to baseline. These outcomes were likely reflected in the initial improvement and subsequent long-term stable visual acuity observed in VISUAL III. Additionally, CST decreased over time in patients with active uveitis. Because there are differences in how the 3 OCT systems determine CST, we reported the data separately for each OCT system to control for differences in software algorithms.
Previous studies have demonstrated that treatment with adalimumab significantly prolongs time to TF (e.g., flare) after corticosteroid discontinuation. 17, 19 However, in clinical practice, patients may receive systemic or topical corticosteroid support as needed for uveitis control; as such, corticosteroids were permitted as needed in the current trial. Patients who enrolled with active uveitis were receiving a mean corticosteroid dose of nearly 14 mg/day despite recommendations that prolonged use of doses >10 mg/day be avoided because of well-characterized systemic side effects, risk of cataract, and increased intraocular pressure. 10, 18, 27 Adalimumab treatment decreased the mean dose of systemic corticosteroids in these patients by more than 80%, to <3 mg/day, which is below the commonly accepted clinical threshold of 5 mg of daily prednisone-equivalent dose. 9, 10, 21 Furthermore, by week 78, only 5% of patients in the overall study population had discontinued the trial because of a lack of efficacy. Treatment with adalimumab was well tolerated in this study. There was a low incidence of AEs of special interest, and no new safety signals were detected beyond those previously reported with biologic therapies targeting TNF-a 28, 29 and those reported in the VISUAL I and II trials. 8, 17 The incidence of demyelinating disorders reported in the VISUAL III study (0.5/100 PY) was higher than that observed in clinical trials for other adalimumab indications ( 0.1/100 PY). However, the observed rate is comparable to the background rate reported in patients with uveitis who were not exposed to adalimumab (Guo D, et al, manuscript in progress). 30 Furthermore, there is a known association between anterior and intermediate uveitis and demyelinating disorders 31e33 ; for example, an estimated 7% to 10% of patients with intermediate uveitis also have multiple sclerosis. 34, 35 There were no significant changes from baseline for laboratory tests or vital signs (data not shown).
This study had limitations; because the VISUAL III study was meant to reflect real-life clinical practice, the use of concomitant immunosuppressants and corticosteroids was allowed. We hypothesized that adalimumab accounted for the favorable inflammation control observed during the VISUAL III trial, which occurred in the context of corticosteroid tapering, as described previously. However, in the absence of a control group and in the context of use of other immunosuppressive agents, drug efficacy cannot be determined in comparison with eyes that were not treated with adalimumab. In addition, there was loss of patient data over time owing to premature discontinuation. Thus, our results using the conservative NRI method may underestimate the efficacy of adalimumab observed in a real-world setting. The true efficacy of adalimumab in patients with uveitis may lie somewhere between the as-observed analysis and the analysis imputing nonresponse for patients who discontinued. Additionally, in patients who entered the study with inactive uveitis, 15% were not in quiescence at baseline (i.e., did not meet the criteria of no active inflammatory lesions, anterior chamber cell grade 0.5þ, and vitreous haze grade 0.5þ in both eyes); future analyses will need to address this patient subgroup. Additional studies are needed to further clarify the long-term efficacy of adalimumab, including analyses that stratify patients by response to adalimumab and permit other therapies for the nonresponder subgroups. Other caveats include inherent variations among the 3 OCT systems and possible bias in the LOCF analysis of OCT data; the last available CST values were assumed to remain constant in missing patients.
This study had several strengths. The patient population was large, considering that noninfectious uveitis is an uncommon disease, estimated to affect fewer than 0.4% of people worldwide. 5, 6 Notably, all patients had the opportunity to complete 78 weeks of follow-up by the interim cutoff date, October 31, 2016. Further, by allowing the use of concomitant treatments as needed (corticosteroids and systemic immunomodulators), this study reflected a clinically relevant, real-world approach to uveitis management.
In conclusion, in patients with noninfectious intermediate, posterior, or panuveitis who received adalimumab (40 mg every other week), disease was controlled with minimal corticosteroid support. About two thirds of patients who entered VISUAL III with active uveitis achieved quiescence by week 78 with a substantially reduced uveitis-related corticosteroid dose; additionally, mean BCVA was improved over time in patients with active uveitis. About three quarters of patients who entered VISUAL III with inactive uveitis had maintained quiescence at week 78, with 93% of these patients achieving corticosteroid-free quiescence; most patients had stable BCVA throughout follow-up. Most patients had no active inflammatory lesions and had anterior chamber cell and vitreous haze grades 0.5þ through 78 weeks of open-label adalimumab treatment, regardless of active or inactive disease at VISUAL III entry. The safety profile was consistent with the known safety profile of adalimumab and the underlying disease. These data suggest that adalimumab can be used for intermediate, posterior, and panuveitis as an important therapeutic option allowing patients to achieve and maintain long-term disease control with or without adjunctive corticosteroids or immunomodulators. Longer-term follow-up in VISUAL III is ongoing.
